Is Brazil’s R$971-million medical cannabis market about to open its doors to domestic cultivation — and what does that mean for international operators?
On February 3, 2026, Brazil’s National Health Surveillance Agency (ANVISA) published five landmark resolutions that fundamentally reshape the country’s medical cannabis landscape. The ANVISA cannabis resolutions 2026 — numbered RDC 1,011 through RDC 1,015 — represent the most significant regulatory shift since Brazil first permitted cannabis products under RDC 327/2019. Unanimously approved by ANVISA’s Collegiate Board on January 28, 2026, these resolutions comply with the Superior Court of Justice (STJ) ruling in November 2024 (IAC No. 16), which recognized the legality of cultivating Cannabis sativa for medical and pharmaceutical purposes and ordered ANVISA to regulate the activity.
Brazil is no longer an import-only market. With a medical cannabis sector valued at R$971 million in 2025, more than 672,000 registered patients, and year-over-year patient growth of 56%, the new framework authorizes domestic cultivation, expands product access, and creates a regulatory sandbox for patient associations. This article breaks down each resolution, the key compliance dates, and what international operators, investors, and compliance officers need to act on now.
What the ANVISA Cannabis Resolutions 2026 Change: A Complete Timeline
Five resolutions, three different effective dates, and a transition period extending into August 2027. The staggered timeline creates distinct compliance windows that operators must plan around.
Key Dates at a Glance
| Date | Event | Resolution(s) |
|---|---|---|
| January 28, 2026 | ANVISA Collegiate Board unanimously approves all five RDCs | RDC 1,011 — 1,015 |
| February 3, 2026 | Published in Diario Oficial da Uniao; RDC 1,011 takes effect immediately | RDC 1,011 |
| April — July 2026 (expected) | ANVISA public call for regulatory sandbox applications | RDC 1,014 |
| May 4, 2026 | New sanitary rules for cannabis products take effect (90 days) | RDC 1,015 |
| August 4, 2026 | Cultivation and sandbox rules take effect (180 days) | RDC 1,012, 1,013, 1,014 |
| August 5, 2027 | Transition deadline for entities operating under judicial authorization | RDC 1,012, 1,013 |
Why These Resolutions Exist
The ANVISA cannabis resolutions did not emerge from the legislature. In November 2024, the STJ issued a binding ruling (IAC No. 16) recognizing the legality of cannabis cultivation for medical purposes and ordering ANVISA to regulate the activity. The five RDCs are ANVISA complying with a judicial mandate — not a congressional act. This pattern is increasingly common across Latin America, where the cannabis industry in Latin America continues evolving through courts and regulatory agencies rather than parliaments.
Breaking Down Brazil’s Five New Cannabis Resolutions
Each resolution serves a distinct function. Together, they create an interlocking regulatory framework covering controlled substances classification, research cultivation, commercial cultivation, patient association operations, and product sanitary standards.
RDC 1,011 — Controlled Substances List Update
RDC 1,011 updates Portaria SVS/MS No. 344/1998 — Brazil’s master controlled substances framework — to formally embed cannabis classifications. Effective immediately on February 3, 2026, it classifies products with THC above 0.2% under Lista A3 (Yellow Receipt) and products with THC at or below 0.2% under Lista B1 (Blue Receipt). Dentists are formally added as authorized prescribers. This creates permanent regulatory standing for cannabis within Portaria 344, making RDC 1,011 the legal bedrock on which the other four resolutions operate.
RDC 1,012 — Cannabis Cultivation for Scientific Research
RDC 1,012 establishes a formal pathway for research institutions to cultivate cannabis — crucially, with no THC limit. Only ANVISA-accredited legal entities (universities, research institutions, scientific centers) may cultivate, each requiring a Special Authorization (AE). Commercialization is prohibited; material transfer is permitted only between authorized institutions. Import of seeds and plant material is authorized for research.
Major beneficiaries include Fiocruz, UNICAMP, and Embrapa, which recently launched a 12-year hemp research program (2025-2037). Effective August 4, 2026, with entities already cultivating under judicial decisions given until August 5, 2027.
RDC 1,013 — Cannabis Cultivation for Medicinal and Pharmaceutical Purposes
RDC 1,013 is the headline resolution. It legalizes, for the first time, cultivation of cannabis with THC at or below 0.3% for medicinal and pharmaceutical purposes by authorized establishments in Brazil.
What RDC 1,013 Cannabis Brazil Cultivation Rules Actually Require
The Brazil cannabis cultivation rules under RDC 1,013 are rigorous. Establishments must obtain ANVISA’s Special Authorization (AE) through an application requiring geographic coordinates, monitoring plans, organizational structure documentation, production estimates, and proof of genetic origin of seeds or seedlings.
Import of seeds, seedlings, and plant inputs is now authorized — a major shift from the previous framework. Export of plant material remains expressly prohibited. Cultivators must comply with Good Agricultural Practices (GAP), Good Pharmaceutical Practices (GMP), environmental norms, and workplace safety standards.
Domestic cultivation under RDC 1,013 can fundamentally reshape supply chains and lower patient costs. The effective date is August 4, 2026, and the framework draws comparisons to cannabis license in Peru and other Latin American markets that have opened cultivation pathways.
RDC 1,014 — Regulatory Sandbox for Patient Associations
RDC 1,014 creates a “regulatory sandbox” where non-profit patient associations can cultivate cannabis, produce APIs, and prepare products for their registered members under direct ANVISA supervision. Entry is via public call (expected April-July 2026), with up to five years of authorized operation. THC is capped at 0.3%, and commercialization is absolutely prohibited.
The first-year cost is estimated at R$439,000 to R$1,084,000 for associations serving 100-300 members — substantial for non-profits, but far less than full pharmaceutical compliance. The 259+ registered patient associations and 147,000+ patients in the association model now have a legal pathway replacing precarious habeas corpus cultivation. Countries like Argentina have developed Argentine cannabis clubs under similar models, offering useful comparative precedent.
ANVISA RDC 1,015 — Comprehensive Sanitary Rules (Replacing RDC 327/2019)
ANVISA RDC 1,015 replaces RDC 327/2019 and takes effect May 4, 2026 — earlier than the cultivation resolutions. It establishes comprehensive sanitary rules for manufacturing, importing, and commercializing cannabis products.
What Changed from RDC 327/2019 to ANVISA RDC 1,015
| Feature | RDC 327/2019 (Old) | ANVISA RDC 1,015 (New) |
|---|---|---|
| Higher-THC access | Terminal/palliative only | Serious debilitating diseases |
| Administration routes | Oral only | Oral, inhalation, buccal, sublingual, dermal |
| Compounding pharmacies | Not authorized | Authorized for CBD products (98%+ purity) |
| Prescribers | Physicians only | Physicians and dentists |
| Authorization validity | 5 years, non-extendable | 5 years + one 5-year extension |
Under ANVISA RDC 1,015, companies require AFE (Operating License), AE (Special Authorization), and CBPF (GMP Certificate); importers also need CGDP. SNGPC integration is mandatory for full traceability. All labeling must be in Brazilian Portuguese with tamper-evident, child-resistant packaging. A multi-agency committee (ANVISA + Ministry of Justice + Ministry of Health + MAPA) oversees production. Foreign companies must partner with a Brazilian pharmaceutical entity.
What Brazil Cannabis Cultivation Rules Mean for International Operators and Investors
Market Opportunity by the Numbers
Brazil’s medical cannabis market reached R$971 million in 2025 with a projected CAGR of 24.6% through 2030. The patient base of 672,000+ is growing at 56% year over year, putting Brazil on track to surpass one million patients by 2026-2027. The country already ranks number one in Latin America and in the global top ten for medical cannabis. Patient access currently splits across three channels: 47% through personal imports (RDC 660), 31% through pharmacy products (RDC 327), and 22% through patient associations. Over 500 companies currently export cannabis products to Brazil — domestic production under the new ANVISA cannabis resolutions will fundamentally reshape these supply chains and open new entry pathways for international operators.
Entry Pathways Under the New Framework
The ANVISA cannabis resolutions 2026 create multiple entry points:
- Manufacturing/cultivation: Obtain AE from ANVISA; partner with a Brazilian pharmaceutical entity; meet GMP standards (CBPF/WHO GMP/PIC/S)
- Import: Still viable but long-term risk as domestic production scales; CGDP required
- Association support: Technology and compliance services for 259+ associations entering the sandbox
- Research partnerships: Collaborate with Brazilian institutions under RDC 1,012; no THC restriction
International operators should also examine cannabis license in Ecuador and other regional frameworks as part of broader Latin American market strategy.
What Investors Should Watch
- Sandbox public call timeline (April-July 2026): ANVISA’s selection criteria will signal enforcement posture
- Transition deadline compliance (August 5, 2027): How many entities successfully move from judicial authorization to formal AE approval
- RDC 660 import trends: Declining personal import authorizations (currently 500+/day) would signal domestic production meeting demand
Compliance Requirements for Producers Under the New ANVISA Framework
Cultivation Compliance Checklist (RDC 1,012 and RDC 1,013)
Any entity intending to cultivate cannabis in Brazil must address these Brazil cannabis cultivation rules:
- Obtain Special Authorization (AE) from ANVISA before any cultivation
- Submit geographic coordinates to ANVISA
- Provide monitoring plans with environmental and security protocols
- Document organizational structure and production estimates
- Provide proof of genetic origin of all seeds or seedlings
- Comply with GAP, GMP, environmental norms, and workplace safety standards
- Implement laboratory testing and full traceability for all cultivated material
- No export (RDC 1,013); no commercialization of research material (RDC 1,012)
Manufacturing and Import Compliance (RDC 1,015)
- AFE + AE + CBPF (plus CGDP for importers)
- Full SNGPC integration for traceability from manufacture through dispensing
- Portuguese-language labeling and documentation
- CBD concentration at least five times greater than THC
- Tamper-evident, child-resistant packaging
- Multi-agency oversight compliance
How Seed-to-Sale Tracking Supports ANVISA Compliance
The ANVISA cannabis resolutions 2026 traceability mandates — SNGPC integration, multi-agency reporting, batch-level documentation — require purpose-built digital infrastructure. Operators cannot meet these requirements with manual systems at scale.
GrowerIQ’s platform is built for multi-jurisdiction regulatory environments where cultivators and manufacturers must demonstrate chain-of-custody tracking to multiple oversight bodies simultaneously — precisely the scenario Brazil’s new multi-agency committee creates. From cultivation analytics and digital master batch records to automated compliance reporting, seed-to-sale platforms map directly to the new requirements.
The compliance window is narrow: RDC 1,015 takes effect May 4, 2026; cultivation and sandbox rules activate August 4, 2026; judicial authorization transitions must complete by August 5, 2027. Operators looking at marijuana cultivation in Argentina and other markets will recognize the pattern: regulatory frameworks demand digital compliance systems from day one.
Key Takeaways
- Five RDCs, one framework: RDC 1,011 through RDC 1,015 collectively create Brazil’s most comprehensive medical cannabis regulatory system, replacing RDC 327/2019.
- Domestic cultivation authorized: Hemp cultivation (THC at or below 0.3%) is permitted for the first time under RDC 1,013. Research cultivation under RDC 1,012 has no THC limit.
- Three compliance deadlines: May 4, 2026 (RDC 1,015), August 4, 2026 (RDC 1,012, 1,013, 1,014), and August 5, 2027 (transition for entities under judicial authorization).
- R$971 million and growing: Brazil is Latin America’s largest medical cannabis market, with 672,000+ patients and 56% annual growth.
- Traceability is law: SNGPC integration and multi-agency reporting under the new ANVISA cannabis resolutions require digital seed-to-sale tracking for every operator.
Frequently Asked Questions About ANVISA Cannabis Resolutions 2026
What are the ANVISA cannabis resolutions 2026 and when do they take effect?
The ANVISA cannabis resolutions 2026 are five RDCs (1,011 through 1,015) published February 3, 2026, creating the most comprehensive cannabis regulatory framework in Brazilian history. RDC 1,011 took effect immediately. RDC 1,015 takes effect May 4, 2026. RDC 1,012, 1,013, and 1,014 take effect August 4, 2026. Entities under judicial authorization have until August 5, 2027.
Does RDC 1,013 allow international companies to cultivate cannabis in Brazil?
Yes, with conditions. RDC 1,013 cannabis Brazil rules permit cultivation of cannabis with THC at or below 0.3% for medicinal and pharmaceutical purposes, provided establishments obtain ANVISA’s Special Authorization (AE). Foreign companies can participate but must partner with a Brazilian pharmaceutical entity. Import of seeds, seedlings, and plant inputs is now authorized under the new framework, but export of plant material and seeds is expressly prohibited. All cultivators must comply with Good Agricultural Practices, Good Pharmaceutical Practices, and environmental and workplace safety standards.
How does the regulatory sandbox (RDC 1,014) work for patient associations?
RDC 1,014 allows non-profit patient associations to cultivate and prepare products exclusively for registered members under ANVISA supervision. Associations apply through a public call (expected April-July 2026) and operate for up to five years. First-year investment is estimated at R$439,000 to R$1,084,000 for 100-300 members. The 40+ associations currently cultivating under judicial authorization must transition by August 5, 2027.
What changed between RDC 327/2019 and ANVISA RDC 1,015?
ANVISA RDC 1,015 replaces RDC 327/2019 with several significant expansions. Higher-THC products (above 0.2% THC) are now available for patients with serious debilitating diseases — previously, access was limited to terminal and palliative care only. New administration routes include inhalation, buccal, sublingual, and dermal (previously oral only). Compounding pharmacies are now authorized for CBD products at 98%+ purity. Dentists have been added as authorized prescribers. Authorization validity extends to five years with one five-year renewal. SNGPC traceability integration is now mandatory, and a multi-agency oversight committee has been established.
Ready to Enter Brazil’s Growing Cannabis Market?
See how GrowerIQ’s seed-to-sale platform helps cannabis producers meet Brazil’s new ANVISA compliance requirements from day one.
REQUEST DEMO
About GrowerIQ
GrowerIQ is changing the way producers use software - transforming a regulatory requirement into a robust platform to learn, analyze, and improve performance.
To find out more about GrowerIQ and how we can help, fill out the form to the right, start a chat, or contact us.